RT Journal Article
SR Electronic
T1 CD19<sup>+</sup>IgD<sup>+</sup>CD27<sup>-</sup> naïve B Cells as predictors of humoral response to COVID-19 mRNA vaccination in immunocompromised patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.08.11.21261898
DO 10.1101/2021.08.11.21261898
A1 Schulz, Eduard
A1 Hodl, Isabel
A1 Forstner, Patrick
A1 Hatzl, Stefan
A1 Sareban, Nazanin
A1 Moritz, Martina
A1 Fessler, Johannes
A1 Dreo, Barbara
A1 Uhl, Barbara
A1 Url, Claudia
A1 Grisold, Andrea
A1 Khalil, Michael
A1 Kleinhappl, Barbara
A1 Enzinger, Christian
A1 Stradner, Martin H.
A1 Greinix, Hildegard
A1 Schlenke, Peter
A1 Steinmetz, Ivo
YR 2021
UL http://medrxiv.org/content/early/2021/09/29/2021.08.11.21261898.abstract
AB Immunocompromised patients are considered high-risk and prioritized for vaccination against COVID-19. We aimed to analyze B-cell subsets in these patients to identify potential predictors of humoral vaccination response. Patients (n=120) suffering from hematologic malignancies or other causes of immunodeficiency and healthy controls (n=79) received a full vaccination series with an mRNA vaccine. B-cell subsets were analyzed prior to vaccination. Two independent anti-SARS-CoV-2 immunoassays targeting the receptor-binding domain (RBD) or trimeric S protein (TSP) were performed three to four weeks after the second vaccination. Seroconversion occurred in 100% of healthy controls, in contrast to 67% (RBD) and 82% (TSP) of immunocompromised patients, while only 32% (RBD) and 22% (TSP) achieved antibody levels comparable to those of healthy controls. The number of circulating CD19+IgD+CD27- naïve B cells was strongly associated with antibody levels (ρ=0.761, P&lt;0.001) and the only independent predictor for achieving antibody levels comparable to healthy controls (OR 1.07 per 10-µl increase, 95%CI 1.02–1.12, P=0.009). Receiver operating characteristic analysis identified a cut-off at ≥61 naïve B cells per µl to discriminate between patients with and without an optimal antibody response. Consequently, measuring naïve B cells in immunocompromised hematologic patients could be useful in predicting their humoral vaccination response.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04858607Funding Statementno external funding was receivedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethikkomission der Medizinischen Universitaet GrazAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data will be shared upon request.